ClinicalTrials.gg
TerminatedNCT00642421Updated Feb 9, 2010

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

A Phase 3 interventional study of C2L-OCT-01 PR, 10 or 20 mg and C2L-OCT-01 PR, 20 mg in Acromegaly, sponsored by Ambrilia Biopharma, Inc.. Terminated at 10 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-09.

Sponsored by Ambrilia Biopharma, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Commercial reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Planned enrollment
16th of 25
40 · median 56
Started
2008
with 1 other
Phase 3
12 of 25
1 open now
Registered
11th of 25
by date
Lead sponsor
1 of 25
Ambrilia Biopharma, Inc.

Among the 25 studies testing octreotide in Acromegaly, this one is the 16th largest by planned enrollment, is one of 2 that started in 2008, is one of 12 in phase 3, and was the 11th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible for entry in this study, patient must:

  • Be greater than or equal to 18 years of age.
  • Have a confirmed diagnosis of acromegaly based on the following criteria:

    1. Typical clinical features and
    2. Mean GH concentration > 1.0 ng/mL following an oral glucose tolerance test (OGTT) and
    3. Elevated serum IGF-1 levels above gender- and age- matched values.
  • Fall into one of the following categories:

    1. Has been treated for at least the last 12 weeks with Sandostatin LAR® 10 mg or 20 mg, every 28 days with well-controlled symptoms of acromegaly and GH concentration \< 2.5 ng/mL at screening or
    2. Be naïve to prolonged release octreotide with a demonstrated tolerance response to a 7-day administration of Sandostatin® immediate release (50 µg s.c. t.i.d.) or
    3. If previously treated with prolonged release octreotide, has stopped such treatment for at least 12 weeks prior to screening.
  • If female and of , must have a negative pregnancy test at screening and be using adequate means of (i.e., oral or trans-dermal contraceptive drugs, intra-uterine device, diaphragm) during the study.
  • Have the ability to understand the requirements of the study, provide written to participate in this study and agree to abide by the study restrictions.

Exclusion Criteria

To be eligible for entry in this study, patient must NOT:

  • If female, be pregnant or lactating.
  • Have been treated with a GH receptor antagonist (pegvisomant) within the last 12 weeks.
  • Have used a dopamine agonist within the last 30 days.
  • Have undergone pituitary surgery within the last 12 weeks.
  • Have undergone radiotherapy within the last two years.
  • Have any ( to octreotide formulation) or non-responders to Sandostatin-LAR® treatment.
  • Be currently treated with Sandostatin-LAR® and have symptoms of acromegaly that would justify, in the Investigator's opinion, a dose modification.
  • Be receiving Sandostatin-LAR® administration every \< 21 or > 35 days.
  • Have a liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or has persistent , AST > 2 X , serum creatinine > 2 X ULN, serum > 2 X ULN.
  • Have any other conditions that could result in altered GH or IGF-1 levels (such as anorexia nervosa, Laron's syndrome, treatment with levodopa or narcotics analgesics, heroin abuse.)
  • Have type I diabetes (insulin-dependent) or uncontrolled type II diabetes (non-insulin-dependent) as indicated by the presence of ketoacidosis or greater than or equal to 10%.
  • Have signs and symptoms potentially related to a tumor compression of the optical chiasm, based on judgment of the investigator.
  • Have symptomatic cholelithiasis.
  • Have received an drug or participated in a clinical trial within the last 30 days.
  • Have clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Population A

    Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.

    Drug: C2L-OCT-01 PR, 10 or 20 mg

  • Experimental
    Population B

    Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.

    Drug: C2L-OCT-01 PR, 20 mg

Interventions

  • The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

    Also known as: octreotide acetate

  • The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

    Also known as: octreotide acetate

06

What researchers measure

Primary outcomes

  1. To assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.

    Time frame: 28-day screening period followed by a 48 to 52 week treatment period and concluding with a end of study visit at 56, 57 or 58 weeks.

Secondary outcomes

  1. To assess biological and clinical activity of C2L-OCT-01 PR by examining the percentage of patients with mean growth hormone (GH) <2.5 ng/ml.

    Time frame: Screening, Visits 1 through 11, and End of Study Visit.

  2. To assess the biologic and clinical activity of C2L-OCT-01 PR by examining the mean changes from baseline in GH and IGF-1 concentrations.

    Time frame: Screening, Visits 1 through 11, and End of Study Visit.

  3. To assess the biologic and clinical activity of C2L-OCT-01 PR by examining the acromegaly severity index and patient's health status scores.

    Time frame: Screening, Visit 1 through 11, and End of Study Visit.

  4. To assess biological and clinical activity of C2L-OCT-01 PR by examining the pituitary tumor size.

    Time frame: Screening, Visit 6 and End of Study Visit.

07

Study locations

10 sites
  • UCLA Medical Center Division of Neurosurgery
    Los Angeles, California 90095, United States
  • Stanford University Medical Center
    Stanford, California 94305-5826, United States
  • Kaleida Health/Diabetes Center of WNY
    Buffalo, New York 14206, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • VA Puget Sound Health Care System
    Tacoma, Washington 98489, United States
  • Republican Centre for Medical Rehabilitation and Water-therapy
    Minsk, Belarus
  • Semmelweis Egyetem Altalanos Orvostudomanyi
    Budapest, Hungary
  • Institute of Endocrinology "C.I. Parhon" Bucharest
    Bucharest, Romania
  • Institute of Endocrinology, University Clinical Center
    Belgrade, Serbia
  • V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine
    Kiev, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2008
First posted
Mar 25, 2008
Start
Feb 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Feb 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00642421
Lead sponsor
Ambrilia Biopharma, Inc.
First posted
Mar 25, 2008
Start date
Feb 2008
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Feb 9, 2010

Study contacts

Raphael Naudin, M.D.
study director · Ambrilia Biopharma, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion